SCHEMBL763156

SCHEMBL763156

NC(=O)c1cnc(Nc2cccc(OCCN3CCOCC3)c2)nc1NC1CC1

nearest known ligand 0.63

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
EGFR P00533 3/20 0.63
ITK Q08881 2/20 0.63
SYK P43405 17/20 0.62
BTK Q06187 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL763187 0.90 SYK (0.71) SYK
SCHEMBL763449 0.84 SYK (0.63) SYK
SCHEMBL737980 0.81 SYK (0.62) EGFRSYKBTK
SCHEMBL3389002 0.79 ULK1 (0.57) EGFRITKSYKBTK
SCHEMBL14976515 0.79 SYK (0.67) EGFRITKSYK
SCHEMBL14976517 0.79 SYK (0.67) EGFRITKSYK
SCHEMBL763389 0.79 SYK (0.76) SYK
SCHEMBL14981797 0.79 SYK (0.67) EGFRITKSYK
SCHEMBL737240 0.78 EGFR (0.59) EGFRSYKBTK
SCHEMBL10129699 0.78 EML4 (0.65)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501944-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2013-08-06 US disclosed
US-8138339-B2 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2012-03-20 US disclosed
US-20090318407-A1 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2009-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318407-A1 Inhibitors of protein kinases SYK, BTK, JAK1 EGFR 966/4885ITK 59/4885SYK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.